Sequential CAR T cell and targeted alpha immunotherapy in disseminated multiple myeloma is a research paper published in Cancer Immunology Immunotherapy (2023). On theSindex it has a DataRank of 0.345. It has been cited 9 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.345
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health, National Cancer Institute
Grant: NIH-R50-CA252135
National Institutes of Health, National Cancer Institute
Grant: NIH-2-R01-CA238429-01
NCI NIH HHS
Grant: R01 CA238429
NCI NIH HHS
Grant: P30 CA033572
NCI NIH HHS
Grant: R50 CA252135
National Institutes of Health
Grant: 5P30CA033572-27
Developmental Funds
National Institutes of Health
Grant: 5R50CA252135-04
Improving Outcomes for Multiple Myeloma Patients through Novel Therapeutic Interventions
National Institutes of Health
Grant: 5R01CA238429-04
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma
City of Hope
Fields of Study
MeSH Terms
Keywords